Nemolizumab (CIM331) is a humanized monoclonal antibody designed to selectively target the interleukin-31 receptor alpha (IL-31RA). By binding to IL-31RA, Nemolizumab effectively inhibits the interaction between interleukin-31 (IL-31) and its receptor, thereby blocking the downstream signaling pathways. This inhibition is clinically relevant as it contributes to the reduction of pruritus (itching) and sleep disturbances associated with various dermatological conditions, including atopic dermatitis (AD). Nemolizumab is currently under investigation for its therapeutic potential and efficacy in treating symptoms of AD and related conditions.
Nemolizumab (CIM331) is a humanized monoclonal antibody designed to selectively target the interleukin-31 receptor alpha (IL-31RA). By binding to IL-31RA, Nemolizumab effectively inhibits the interaction between interleukin-31 (IL-31) and its receptor, thereby blocking the downstream signaling pathways. This inhibition is clinically relevant as it contributes to the reduction of pruritus (itching) and sleep disturbances associated with various dermatological conditions, including atopic dermatitis (AD). Nemolizumab is currently under investigation for its therapeutic potential and efficacy in treating symptoms of AD and related conditions.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
